BIRIBA Tablets (Tenofovir Disoproxil Fumarate)

Adult dose

Adults: For the treatment of HIV-1 or chronic hepatitis B, take 1 tablet (300mg) once daily. It may be taken with or without food. The optimal duration of treatment for chronic hepatitis B is unknown. Patients with a baseline creatinine clearance of <50mL/min: For a creatinine clearance of 30-49mL/min, take 300mg every 48 hours; for 10-29mL/min, take 300mg every 72-96 hours; for patients receiving hemodialysis, take 300mg every 7 days or approximately 12 hours after completion of a total dialysis session. Assuming 3 hemodialysis sessions of approximately 4 hours each per week, administer once weekly. This medicine should be administered after dialysis is completed. Patients with mild renal impairment: No adjustment to the dosing interval of this medicine is necessary for a creatinine clearance of 50-80mL/min. Regularly monitor the estimated creatinine clearance, serum phosphate, urine glucose, and urine protein. There are no dosing guidelines for patients with a creatinine clearance below 10mL/min who are not receiving hemodialysis.

Child dose

Pediatric patients aged 12 years and older (35kg or more): For the treatment of HIV-1 or chronic hepatitis B, take 1 tablet (300mg) once daily. It may be taken with or without food. Pediatric patients with chronic hepatitis B weighing less than 35kg: Safety and efficacy have not been established. Pediatric patients with renal impairment: There are no data to support dose recommendations.

Discontinuing this medication may lead to a rapid deterioration of hepatitis, so regular liver condition tests should be performed for several months after stopping treatment. Patients with allergies to any ingredient contained in this medication or those with a genetic lactose intolerance should not take it. This medication should not be taken with certain other drugs, so it is essential to consult a physician if other medications are being taken. Patients with reduced kidney function should undergo kidney function tests before taking this medication, and kidney status should be monitored regularly during treatment. This medication may affect bone health, so patients with osteoporosis or a risk of fractures should consider bone density testing and take calcium and vitamin D supplements if necessary. If unusual pain or muscle weakness occurs during treatment, medical professionals should be notified immediately. During pregnancy, this medication should only be used when absolutely necessary, and it is advisable for breastfeeding mothers to avoid breastfeeding while taking this medication. Use is recommended only for patients over 12 years of age or weighing more than 35kg; safety and efficacy have not been established for younger patients or those weighing less than this. Elderly patients should be cautious about taking this medication due to the potential for reduced kidney and liver function. In case of overdose, immediate medical assistance should be sought, and if necessary, blood dialysis can be performed to remove this medication. This medication should be stored at room temperature and kept safe from children's access.

• Worsening hepatitis
• acute renal failure
• Fanconi syndrome
• hypophosphatemia
• kidney impairment
• bone pain
• limb pain
• fractures
• muscle pain
• proximal renal tubular disease

This medication should be stored in a tightly sealed container to protect it from air and moisture, and it is recommended to keep it at a temperature between 1 and 30 degrees Celsius. Storing it this way will help maintain the effectiveness of the medication for a longer period.

Appearance

Pale blue almond-shaped film-coated tablets

Package unit

30 tablets per bottle